Entering text into the input field will update the search result below

European advisory group backs AstraZeneca combo pill for T2D

Sep. 20, 2019 7:05 AM ETAstraZeneca PLC (AZN) StockAZNBy: Douglas W. House, SA News Editor
  • The European Medicine Agency's advisory group CHMP has adopted a positive opinion recommending approval of AstraZeneca's (NYSE:AZN) Qtrilmet (850 mg metformin hydrochloride, 2.5 mg saxagliptin and 5 mg dapagliflozin or 1000 mg metformin hydrochloride, 2.5 mg saxagliptin and 5 mg dapagliflozin) to improve glycaemic control in adults with type 2 diabetes (T2D) when metformin with or without sulphonylurea and either saxagliptin or dapagliflozin does not provide adequate glycaemic control and who are already receiving metformin and saxagliptin and dapagliflozin.
  • A final decision from the European Commission usually takes ~60 days.

Recommended For You

More Trending News

About AZN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
AZN--
AstraZeneca PLC